RA CAPITAL MANAGEMENT, L.P.
CIK 1346824 · last filed 2026-07-22
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.24B
Companies
45
Total Filings
101
Lifetime Open-Market Net
-$102.39B
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| FRNM | Director | 908,103 | — | — | $0 | 1 | 2026-07-22 |
| HOWL | Director | 303,719 | $0.45 | $136.5K | -$583.7K | 3 | 2026-06-22 |
| SION | Director | 661,019 | $46.55 | $30.77M | $114.30M | 3 | 2026-06-18 |
| NKTX | Director | 2,271,796 | $2.22 | $5.04M | $180.00M | 2 | 2026-06-11 |
| BCAX | Director | — | $26.88 | — | $0 | 1 | 2026-06-10 |
| COAG | 10%+ Owner | 6,375,972 | $47.26 | $301.33M | $479.1K | 1 | 2026-05-21 |
| ACET | 10%+ Owner | 1,033,605 | $8.20 | $8.48M | $6.42M | 1 | 2026-04-13 |
| WVE | Director | 23,157,567 | $5.89 | $136.40M | $328.50M | 5 | 2026-03-30 |
| Climb Bio, Inc. (ELYM) Delisted | Director | 2,866,375 | $5.11 | $14.65M | $174.2K | 1 | 2026-01-07 |
| MLYS | Director | 1,867,229 | $26.95 | $50.32M | $150.00M | 3 | 2025-09-08 |
| SEPN | Director | — | $33.97 | — | $0 | 1 | 2025-06-20 |
| Cidara Therapeutics, Inc. (CDTX) Delisted | Director | — | $221.38 | — | $0 | 1 | 2025-06-18 |
| TYRA | Director | 442,721 | $30.88 | $13.67M | $9.52M | 2 | 2025-06-11 |
| VOR | Director | 426,996 | $20.00 | $8.54M | $214.53M | 4 | 2025-05-23 |
| SLDB | Director | 4,192,216 | $7.97 | $33.41M | $25.00M | 3 | 2025-02-21 |
| ANTX | 10%+ Owner | 1,725,348 | $4.70 | $8.11M | $105.98M | 3 | 2024-08-13 |
| SPRY | Director | 2,106,774 | $5.67 | $11.95M | $0 | 2 | 2024-06-24 |
| ABOS | Director | — | $2.28 | — | $0 | 3 | 2024-06-10 |
| BOLD | 10%+ Owner | 1,587,912 | $2.47 | $3.92M | $25.00M | 1 | 2024-04-04 |
| Icosavax, Inc. (ICVX) Delisted | Director | — | $15.31 | — | $0 | 1 | 2023-06-08 |
| DICE Therapeutics, Inc. (DICE) Delisted | Director | 786,407 | $47.55 | $37.39M | $141.28M | 3 | 2023-03-30 |
| IMRA | 10%+ Owner | 970,005 | $14.49 | $14.06M | $10.06M | 1 | 2023-01-05 |
| FULC | 10%+ Owner | 7,824,600 | $3.72 | $29.11M | $52.30M | 1 | 2022-12-16 |
| JANX | Director | — | $15.00 | — | $0 | 1 | 2022-06-16 |
| iTeos Therapeutics, Inc. (ITOS) Delisted | Director | 3,155,667 | $10.15 | $32.03M | $0 | 2 | 2022-06-10 |
| Forma Therapeutics Holdings, Inc. (FMTX) Delisted | Director | 1,511,425 | $20.01 | $30.24M | $0 | 1 | 2022-06-09 |
| KALA | Director | 2,819 | $0.66 | $1.9K | $16.58M | 4 | 2022-05-26 |
| PEPG | Director | 1,052,851 | $1.83 | $1.93M | $193.75M | 2 | 2022-05-12 |
| Satsuma Pharmaceuticals, Inc. (STSA) Delisted | Director | 4,681,858 | $1.10 | $5.15M | $60.00M | 2 | 2020-12-07 |
| RYTM | 4,568,464 | $108.04 | $493.58M | -$28.12M | 1 | 2020-12-04 | |
| PMVP | 10%+ Owner | 1,710,265 | $1.10 | $1.88M | $51.30M | 1 | 2020-09-29 |
| VSTM | 10%+ Owner | 1,345,171 | $6.23 | $8.38M | -$8.88M | 1 | 2020-06-29 |
| PHAT | 10%+ Owner | 3,707,408 | $11.66 | $43.23M | $5.96M | 1 | 2020-03-31 |
| Synthorx, Inc. (THOR) Delisted | 10%+ Owner | 0 | — | — | $100.00M | 2 | 2020-01-24 |
| Ra Pharmaceuticals, Inc. (RARX) Delisted | Director | 4,858,260 | — | — | $98.10M | 5 | 2019-06-13 |
| ARVN | 3,138,412 | $8.20 | $25.73M | $48.00M | 1 | 2018-10-03 | |
| KalVista Pharmaceuticals, Inc. (KALV) Delisted | Director | 591,070 | $27.00 | $15.96M | $0 | 1 | 2016-11-23 |
| ACRS | 10%+ Owner | 2,469,552 | $5.33 | $13.16M | $59.06M | 3 | 2015-10-30 |
| SANGAMO THERAPEUTICS, INC (SGMO) Delisted | 2,829,441 | $0.18 | $502.5K | -$82.39M | 2 | 2015-02-18 | |
| ACHILLION PHARMACEUTICALS INC (ACHN) Delisted | 10%+ Owner | 9,700,000 | — | — | -$104.29B | 8 | 2014-09-26 |
| DERMA SCIENCES, INC. (DSCI) Delisted | 1,884,876 | — | — | -$10.65M | 1 | 2014-01-13 | |
| BIOSPECIFICS TECHNOLOGIES CORP (BSTC) Delisted | 10%+ Owner | 626,462 | — | — | -$3.54M | 6 | 2010-02-26 |
| SEQUENOM INC (SQNM) Delisted | 10%+ Owner | 5,506,093 | — | — | $28.98M | 3 | 2008-07-15 |
| LIPID SCIENCES INC/ (LIPD) Delisted | 10%+ Owner | 3,705,312 | — | — | -$56.2K | 1 | 2008-03-31 |
| ARADIGM CORP (ARDM) Delisted | 10%+ Owner | 187,245 | — | — | $5.21M | 2 | 2007-11-05 |
Recent Filings · Page 2 of 11
101 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-11-24 | SION | Sell (S) | −181,896 | -$7.20M | EDGAR |
| 2025-11-12 | — | Mixed | +3,458,770 | $20.00M | |
| 2025-09-08 | MLYS | Buy (P) | +5,882,350 | $150.00M | EDGAR |
| 2025-06-20 | SEPN | Grant (A) | — | $0 | EDGAR |
| 2025-06-18 | Cidara Therapeutics, Inc. (CDTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-06-11 | TYRA | Buy (P) | +934,250 | $9.52M | EDGAR |
| 2025-05-23 | VOR | Grant (A) | — | $0 | EDGAR |
| 2025-02-24 | MLYS | Grant (A) | — | $0 | EDGAR |
| 2025-02-21 | SLDB | Buy (P) | — | $0 | EDGAR |
| 2025-02-10 | SION | Mixed | +54,458,958 | $121.50M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.